Extracellular galectin 3 may influence tumour progression by impeding the endocytosis of key receptors, including TGFβ and EGF, while at the same time inducing endocytosis of β1 integrins (Furtak et al., 2001; Partridge et al., 2004). The gene discussed is EGF; the disease is neoplasm.